Literature DB >> 22202459

Integrative genomic identification of genes on 8p associated with hepatocellular carcinoma progression and patient survival.

Stephanie Roessler1, Ezhou Lori Long, Anuradha Budhu, Yidong Chen, Xuelian Zhao, Junfang Ji, Robert Walker, Hu-Liang Jia, Qing-Hai Ye, Lun-Xiu Qin, Zhao-You Tang, Ping He, Kent W Hunter, Snorri S Thorgeirsson, Paul S Meltzer, Xin Wei Wang.   

Abstract

BACKGROUND & AIMS: Hepatocellular carcinoma (HCC) is an aggressive malignancy; its mechanisms of development and progression are poorly understood. We used an integrative approach to identify HCC driver genes, defined as genes whose copy numbers associate with gene expression and cancer progression.
METHODS: We combined data from high-resolution, array-based comparative genomic hybridization and transcriptome analysis of HCC samples from 76 patients with hepatitis B virus infection with data on patient survival times. Candidate genes were functionally validated using in vitro and in vivo models.
RESULTS: Unsupervised analyses of array comparative genomic hybridization data associated loss of chromosome 8p with poor outcome (reduced survival time); somatic copy number alterations correlated with expression of 27.3% of genes analyzed. We associated expression levels of 10 of these genes with patient survival times in 2 independent cohorts (comprising 319 cases of HCC with mixed etiology) and 3 breast cancer cohorts (637 cases). Among the 10-gene signature, a cluster of 6 genes on 8p, (DLC1, CCDC25, ELP3, PROSC, SH2D4A, and SORBS3) were deleted in HCCs from patients with poor outcomes. In vitro and in vivo analyses indicated that the products of PROSC, SH2D4A, and SORBS3 have tumor-suppressive activities, along with the known tumor suppressor gene DLC1.
CONCLUSIONS: We used an unbiased approach to identify 10 genes associated with HCC progression. These might be used in assisting diagnosis and to stage tumors based on gene expression patterns.
Copyright © 2012 AGA Institute. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22202459      PMCID: PMC3321110          DOI: 10.1053/j.gastro.2011.12.039

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  36 in total

Review 1.  The hallmarks of cancer.

Authors:  D Hanahan; R A Weinberg
Journal:  Cell       Date:  2000-01-07       Impact factor: 41.582

2.  Methods for assessing reproducibility of clustering patterns observed in analyses of microarray data.

Authors:  Lisa M McShane; Michael D Radmacher; Boris Freidlin; Ren Yu; Ming-Chung Li; Richard Simon
Journal:  Bioinformatics       Date:  2002-11       Impact factor: 6.937

3.  Molecular pathogenesis of human hepatocellular carcinoma.

Authors:  Snorri S Thorgeirsson; Joe W Grisham
Journal:  Nat Genet       Date:  2002-08       Impact factor: 38.330

Review 4.  Hepatocellular carcinoma pathogenesis: from genes to environment.

Authors:  Paraskevi A Farazi; Ronald A DePinho
Journal:  Nat Rev Cancer       Date:  2006-09       Impact factor: 60.716

5.  The association of chromosome 8p deletion and tumor metastasis in human hepatocellular carcinoma.

Authors:  L X Qin; Z Y Tang; J S Sham; Z C Ma; S L Ye; X D Zhou; Z Q Wu; J M Trent; X Y Guan
Journal:  Cancer Res       Date:  1999-11-15       Impact factor: 12.701

6.  Predictive value of liver cell dysplasia for development of hepatocellular carcinoma in patients with non-cirrhotic and cirrhotic chronic viral hepatitis.

Authors:  L Libbrecht; M Craninx; F Nevens; V Desmet; T Roskams
Journal:  Histopathology       Date:  2001-07       Impact factor: 5.087

7.  A unique metastasis gene signature enables prediction of tumor relapse in early-stage hepatocellular carcinoma patients.

Authors:  Stephanie Roessler; Hu-Liang Jia; Anuradha Budhu; Marshonna Forgues; Qing-Hai Ye; Ju-Seog Lee; Snorri S Thorgeirsson; Zhongtang Sun; Zhao-You Tang; Lun-Xiu Qin; Xin Wei Wang
Journal:  Cancer Res       Date:  2010-12-15       Impact factor: 12.701

8.  Etiology-dependent molecular mechanisms in human hepatocarcinogenesis.

Authors:  Christof Schlaeger; Thomas Longerich; Claudia Schiller; Peter Bewerunge; Arianeb Mehrabi; Grischa Toedt; Jörg Kleeff; Volker Ehemann; Roland Eils; Peter Lichter; Peter Schirmacher; Bernhard Radlwimmer
Journal:  Hepatology       Date:  2008-02       Impact factor: 17.425

9.  DNA variants of DLC-1, a candidate tumor suppressor gene in human hepatocellular carcinoma.

Authors:  Sang-Won Park; Marian E Durkin; Snorri S Thorgeirsson; Nicholas C Popescu
Journal:  Int J Oncol       Date:  2003-07       Impact factor: 5.650

Review 10.  DLC-1:a Rho GTPase-activating protein and tumour suppressor.

Authors:  Marian E Durkin; Bao-Zhu Yuan; Xiaoling Zhou; Drazen B Zimonjic; Douglas R Lowy; Snorri S Thorgeirsson; Nicholas C Popescu
Journal:  J Cell Mol Med       Date:  2007 Sep-Oct       Impact factor: 5.310

View more
  161 in total

1.  Genetic and Environmental Models of Circadian Disruption Link SRC-2 Function to Hepatic Pathology.

Authors:  Tiffany Fleet; Erin Stashi; Bokai Zhu; Kimal Rajapakshe; Kathrina L Marcelo; Nicole M Kettner; Blythe K Gorman; Cristian Coarfa; Loning Fu; Bert W O'Malley; Brian York
Journal:  J Biol Rhythms       Date:  2016-07-17       Impact factor: 3.182

2.  PI3K/AKT/mTOR-dependent stabilization of oncogenic far-upstream element binding proteins in hepatocellular carcinoma cells.

Authors:  Jana Samarin; Vibor Laketa; Mona Malz; Stephanie Roessler; Ilan Stein; Elad Horwitz; Stephan Singer; Eleni Dimou; Antonio Cigliano; Michaela Bissinger; Christine Susanne Falk; Xin Chen; Steven Dooley; Eli Pikarsky; Diego Francesco Calvisi; Carsten Schultz; Peter Schirmacher; Kai Breuhahn
Journal:  Hepatology       Date:  2016-01-14       Impact factor: 17.425

3.  The camKK2/camKIV relay is an essential regulator of hepatic cancer.

Authors:  Fumin Lin; Kathrina L Marcelo; Kimal Rajapakshe; Cristian Coarfa; Adam Dean; Nathaniel Wilganowski; Holly Robinson; Eva Sevick; Karl-Dimiter Bissig; Lauren C Goldie; Anthony R Means; Brian York
Journal:  Hepatology       Date:  2015-05-09       Impact factor: 17.425

4.  Somatic copy number profiling from hepatocellular carcinoma circulating tumor cells.

Authors:  Colin M Court; Shuang Hou; Lian Liu; Paul Winograd; Benjamin J DiPardo; Sean X Liu; Pin-Jung Chen; Yazhen Zhu; Matthew Smalley; Ryan Zhang; Saeed Sadeghi; Richard S Finn; Fady M Kaldas; Ronald W Busuttil; Xianghong J Zhou; Hsian-Rong Tseng; James S Tomlinson; Thomas G Graeber; Vatche G Agopian
Journal:  NPJ Precis Oncol       Date:  2020-07-02

5.  The search for precision models clinically relevant to human liver cancer.

Authors:  Wen Xue; Xin W Wang
Journal:  Hepat Oncol       Date:  2015-11-06

6.  The biological and clinical challenge of liver cancer heterogeneity.

Authors:  Xin Wei Wang; Snorri S Thorgeirsson
Journal:  Hepat Oncol       Date:  2014-12-11

Review 7.  The consequences of chromosomal aneuploidy on the transcriptome of cancer cells.

Authors:  Thomas Ried; Yue Hu; Michael J Difilippantonio; B Michael Ghadimi; Marian Grade; Jordi Camps
Journal:  Biochim Biophys Acta       Date:  2012-03-06

Review 8.  Translating metastasis-related biomarkers to the clinic--progress and pitfalls.

Authors:  François-Clément Bidard; Jean-Yves Pierga; Jean-Charles Soria; Jean Paul Thiery
Journal:  Nat Rev Clin Oncol       Date:  2013-02-05       Impact factor: 66.675

9.  High-resolution analysis of DNA copy number alterations in rectal cancer: correlation with metastasis, survival, and mRNA expression.

Authors:  Jérôme Doyen; Eric Letouzé; Laetitia Marisa; Aurélien de Reyniès; Gérard Milano; Marie-Christine Etienne-Grimaldi; Sylviane Olschwang; Jochen Gaedcke; Michael Ghadimi; Jean-Pierre Gérard
Journal:  Strahlenther Onkol       Date:  2014-04-26       Impact factor: 3.621

10.  Cooperative antiproliferative effect of coordinated ectopic expression of DLC1 tumor suppressor protein and silencing of MYC oncogene expression in liver cancer cells: Therapeutic implications.

Authors:  Xuyu Yang; Xiaoling Zhou; Paul Tone; Marian E Durkin; Nicholas C Popescu
Journal:  Oncol Lett       Date:  2016-06-24       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.